Every letter we have printed

The randomised withdrawal design answers one question well and is routinely quoted as answering a different one. It tells you what happens when treatment is removed from people who reached a given point on it. It does not tell you what happens to somebody who stops for their own reasons at their own moment.

A design nobody has run: withdraw, follow, then offer resumption and follow again. It would answer the question most readers actually have, and it is longer and more expensive than anybody has been willing to fund.

Manual reintegration deserves a harder look than the article gives it. Every chromatography data system logs it, the audit trail is right there, and in a regulated environment it would be reviewed. Outside one, nobody ever asks for the trail, and the setting that most affects the answer is the one with the least scrutiny.

On the denominator: I have seen certificates where the counter-ion peak was excluded and certificates where it was not, and the difference on a trifluoroacetate salt is not small. Neither certificate said which had been done. A single line stating what was excluded from the total area would settle it.

Your standing note that nothing in the department is medical advice is doing more work than it appears to. In an area where the evidence is genuinely uncertain, a publication that declines to advise is making a substantive editorial choice rather than a legal one.

Distinguishing expected effects from something that needs attention is the most valuable service a piece like this can perform, and the useful discriminators are pattern and trajectory rather than severity at a moment. Anything that is worsening rather than settling is a different conversation.

The gap between the printed schedule and the practised one is real and your piece is right to describe it without approving of it. The label schedule was the one studied; every departure from it is an extrapolation, and the people making those departures are rarely the people who would be asked to defend them.

Worth noting that the trial schedules were themselves designed for a trial, not for an individual. Fixed intervals suit an analysis plan and a supply chain. Clinicians departing from them are not necessarily departing from evidence; they are departing from a protocol that was built for a different purpose. Nothing in this letter is medical advice.

Supply interruptions are the commonest cause of the situation your article describes, and they are not a clinical decision at all. It is worth connecting the titration question to the supply reporting elsewhere in the issue, because for many readers they are the same story.

The buyer-submitted result and the seller-submitted result are not the same evidence and should not be printed in the same column. Your tables do distinguish them, which I appreciate; most listings do not, and a reader comparing across sources is comparing two different experiments.

Aliquoting breaks the chain silently. If a buyer decants a portion into a second tube before sending it, the laboratory receives a sample the supplier never touched, and any dispute about the result is now unresolvable in both directions.

The suppliers who cooperate with testing are, almost by definition, the ones with least to fear. A programme built on cooperation therefore samples the top of the market and reports the result as though it described the whole of it.

Aggregates are invisible in the sense that matters: they are still the right molecule, so identity confirms, and they may be excluded from a reversed-phase separation entirely by never coming off the column. Whatever stays on the stationary phase is not in the denominator.

Endotoxin is invisible to everything you describe and to everything most buyers commission. It is not a purity question, it is not an identity question, and it is not answered by any instrument in this article. Saying so plainly is worth a paragraph in its own right.

I have spent a week trying to reconcile a certificate’s stated mass of 4113.6 with a figure of 4111.1 I calculated from the sequence, and had convinced myself something was wrong with the vial. It was the isotope convention. Thank you, and also: how is this not stated on every certificate in existence?

Leucine and isoleucine are the standing rebuke to anyone who calls a mass measurement a sequence confirmation. Identical formula, identical mass, different molecule, and no amount of resolving power will separate them without fragmenting the chain. The distinction is not academic for a receptor-binding sequence.

Creatinine is a good example of a value that moves for reasons unrelated to the kidney. Muscle mass, recent exercise and dietary intake all shift it, and during rapid weight change at least two of those are moving at once.

Supplements taken before a draw interfere with several assays directly, which is a chemical interference rather than a physiological effect. It is well documented and almost never asked about.

The comparison with food-hygiene ratings is instructive. Those are dated, they are issued by a body with no commercial relationship to the premises, and they can go down. Three properties, none of which this market’s marks possess, and each of which could be adopted independently.

A note on the buyers who do click through. Of the ones I have spoken to, most read the purity figure and stop. The method, the date and the sample identity are all on the page and are not being read, which suggests the reform needed is in what is emphasised rather than in what is disclosed.

Every custody scheme I have seen assumes a single sample moving forward in time. Real programmes split samples, store halves, retest months later and combine results, and the record-keeping vocabulary has no way to describe that.

I would like the laboratory’s receipt condition printed on the report. Arrived cold, arrived warm, arrived with the seal broken — three observations, made anyway on arrival, and discarded before the document is written.

Publication bias applies here as much as anywhere. A blind programme that publishes only its interesting findings has a denominator problem, and readers have no way to reconstruct the denominator from the outside.

Milligrams, micrograms and volume are three quantities connected by a concentration that the person must calculate, and a concentration derived from a label they cannot verify. Two of the three inputs to that arithmetic are assumptions.

Community calculators are widely used and almost none of them show their working. A tool that produces a number without the intermediate steps cannot be checked, and the checking is the part that catches the error.

Surface disinfection requires a contact time that is printed on the product and almost never observed. Wiping and immediately proceeding achieves very little, and the wait is the active ingredient.

Angle follows length rather than preference. A short needle goes in perpendicular; a longer one into a pinched fold at an angle. Treating the two as interchangeable styles rather than as consequences of the equipment is where most of the confusion sits.

Error reporting in this area is entirely voluntary and therefore entirely unrepresentative. What circulates is the set of mistakes people were willing to describe, which is not the set of mistakes that occurred.

The archives are the good news. Where a service keeps every report it has issued and lets anybody search them, the badge becomes an index entry rather than a claim, and the whole problem changes shape. That capability exists and is barely used.

On our storefront we replaced the badge with a plain line of text giving the molecule, the date and the report number. Conversion fell for a fortnight and recovered, and the questions we now receive are better ones. I mention it because the commercial argument for badges is weaker than sellers assume.

On the archive point: a public record of submissions by vendor would be gamed within a month. Vendors would submit under the names of resellers, or through intermediaries, and the archive would show a distribution as selected as the current one but with a veneer of completeness.

Photographs are a poor substitute for a signature and a good substitute for nothing. Vial, label, seal, packaging, with a timestamp — five minutes of work that has settled every dispute I have been involved in.

Haemolysis is the commonest artefact and it is visible to the laboratory, which is why the comment on the report matters more than any individual value. Several analytes are unusable in a haemolysed sample and the report says so if you read it.

Tourniquet time changes several results measurably, and it is a property of the phlebotomy rather than of the person. A difficult draw produces a different set of numbers from an easy one.

Where a panel is chosen from a menu, people select the analytes they have read about, which produces panels that are wide in the fashionable areas and empty elsewhere. A published example panel with the reasoning would be a useful reference entry.

Two methods are only orthogonal if the mechanisms are independent, and two reversed-phase columns from different vendors are not. We spent a year believing we had orthogonality because the selectivities differed a little, and we had nothing of the kind. The test is the mechanism, not the part number.

Your rule about writing down the lower of two orthogonal figures is sound and I would add the corollary. If the two agree within the repeatability of the method, you have learned something real about the material. If they disagree by three points, you have learned something real about at least one of the methods, and that is worth knowing too.

Our practice is to require the chromatogram alongside the number, and the striking thing is how often the request is met and how rarely anyone makes it. Two years of asking and we have been refused twice. The data is sitting on a laboratory server that nobody is querying.

A modest defence of the percentage. It is the only figure in this trade that is generated by an instrument rather than asserted by a seller, and for all its limits that is not nothing. I would rather argue about what a number means than have no number to argue about.

Constitutive activity of the receptor is measurable and rarely reported, and it changes how a partial effect should be interpreted. It is one of several parameters that would need to be held constant for any cross-paper comparison to mean anything.